Preclinical Pharmacology of Antidepressants

  • Willy Haefely


Anti-depressant drugs have now been available for a quarter of a century. Historically the two main categories of antidepressants, the monoamine oxidase (MAO) inhibitors and the imipramine-1ike drugs, were discovered by serendipity in the clinic.


Antidepressant Drug Noradrenergic Transmission Preclinical Pharmacology Monoamine Uptake Severe Infectious Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E. B. Sigg, Pharmacological studies with tofranil, Canad. psychiat. Ass. J. 4: 75 (1959).PubMedGoogle Scholar
  2. 2.
    W. Haefely, A. Hlirlimann, and H. Thoenen, Scheinbar paradoxe Beeinflussung von peripheren Noradrenalin-Wirkungen durch einige Thymoleptica, Helv. Physiol. Pharmacol. Acta 22: 15 (1964).Google Scholar
  3. 3.
    W. Haefely, M.-A. Ruch-Monachon, M. Jalfre, and R. Schaffner, Interaction of psychotropic agents with central neurotransmitters as revealed by their effects on PGO waves in the cat, Drug Research26: 1036 (1976).PubMedGoogle Scholar
  4. 4.
    G.W. Vogel, Evidence for REM sleep deprivation as the mechanism of action of antidepressant drugs, Progr. Neuropsychopharmacol. & Biol. Psychiat. 7: 343 (1983).CrossRefGoogle Scholar
  5. 5.
    F. Sulser, New perspectives on the mode of action of antidepressant drugs, Trends in Pharmacological Sciences1: 92 (1979).CrossRefGoogle Scholar
  6. 6.
    D.J. Woodward, H.C. Moises, B.D. Waterhouse, B.J. Hoffer, and R. Freedman, Modulatory actions of norepinephrine in the central nervous system, Fed. Proc. 38: 2109 (1979).PubMedGoogle Scholar
  7. 7.
    P. Pole, J. Schneeberger, and W. Haefely, Effects of several centrally active drugs on the sleep-wakefulness cycle of cats, Neuropharmacology18: 259 (1979).CrossRefGoogle Scholar
  8. 8.
    R. Scherschlicht, P. Pole, J. Schneeberger, M. Steiner, and W. Haefely, Selective suppression of rapid eye movement sleep (REMS) in cats by typical and atypical antidepressants, in: “Typical and atypical antidepressants: molecular mechanisms,” E. Costa and G. Racagni, eds., Raven Press, New York (1982).Google Scholar
  9. 9.
    M. Da Prada, H.H. Keller, W.P. Burkard, R. Schaffner, E.P. Bonetti, J.M. Launay, and W. Haefely, Some neuropharmacological effects of Ro 11–2465 — a novel tricyclic antidepressant with potent inhibitory activity on the uptake of 5-HT, in: “Typical and atypical antidepressants: molecular mechanisms”, E. Costa and G. Racagni, eds., Raven Press, New York (1982).Google Scholar
  10. 10.
    H.H. Keller, R. Schaffner, M.D. Carruba, W.P. Burkard, M. Pieri, E.P. Bonetti, R. Scherschlicht, M. Da Prada, and W.E. Haefely, Diclofensine (Ro 8–4650) — a potent inhibitor of monoamine uptake: biochemical and behavioural effects in comparison with nomifensine, in; “Typical and atypical antidepressants: molecular mechanisms”, E. Costa and G. Racagni, eds., Raven Press, New York, (1982).Google Scholar
  11. 11.
    M. Da Prada, R. Kettler, H.H. Keller, and W.E. Haefely, Neurochemical effects in vitro and in vivo of the antidepressant Ro 11–1163, a specific and short-acting MAO-A inhibitor. Mod. Probi. Pharmacopsychiat. 19: 231 (1983).Google Scholar

Copyright information

© Springer Science+Business Media New York 1985

Authors and Affiliations

  • Willy Haefely
    • 1
  1. 1.Pharmaceutical Research DepartmentF. Hoffmann-La Roche & Co., Ltd.BaselSwitzerland

Personalised recommendations